[go: up one dir, main page]

TN2011000254A1 - 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines - Google Patents

3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines

Info

Publication number
TN2011000254A1
TN2011000254A1 TN2011000254A TN2011000254A TN2011000254A1 TN 2011000254 A1 TN2011000254 A1 TN 2011000254A1 TN 2011000254 A TN2011000254 A TN 2011000254A TN 2011000254 A TN2011000254 A TN 2011000254A TN 2011000254 A1 TN2011000254 A1 TN 2011000254A1
Authority
TN
Tunisia
Prior art keywords
aminocyclopentanecarboxamides
modulators
chemokine receptors
compound
formula
Prior art date
Application number
TN2011000254A
Other languages
English (en)
Inventor
Rajesh Venkateswaran Devraj
Wei Huang
Robert Owen Hughes
Jr Donald Joseph Rogier
John Isidro Trujillo
Steve Ronald Turner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2011000254A1 publication Critical patent/TN2011000254A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)

Abstract

IL est proposé un composé de formule I(a) ou I(b) ou un de ses sels pharmaceutiquement acceptable.Dans lequel les divers substituants sont définis dans le present mémoire .
TN2011000254A 2008-11-26 2011-05-18 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines TN2011000254A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11805308P 2008-11-26 2008-11-26
PCT/IB2009/055232 WO2010061329A1 (fr) 2008-11-26 2009-11-20 3-aminocyclopentanecarboxamides en tant que modulateurs des récepteurs de chimiokines

Publications (1)

Publication Number Publication Date
TN2011000254A1 true TN2011000254A1 (fr) 2012-12-17

Family

ID=41693100

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000254A TN2011000254A1 (fr) 2008-11-26 2011-05-18 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines

Country Status (38)

Country Link
US (2) US8293903B2 (fr)
EP (1) EP2370442B9 (fr)
JP (1) JP5108153B2 (fr)
KR (1) KR101374412B1 (fr)
CN (1) CN102227429B (fr)
AP (1) AP3113A (fr)
AU (1) AU2009321221B2 (fr)
BR (1) BRPI0920936A2 (fr)
CA (1) CA2743030C (fr)
CL (1) CL2011001223A1 (fr)
CO (1) CO6361921A2 (fr)
CR (1) CR20110275A (fr)
CU (1) CU24022B1 (fr)
CY (1) CY1114020T1 (fr)
DK (1) DK2370442T5 (fr)
DO (1) DOP2011000154A (fr)
EA (1) EA020470B1 (fr)
EC (1) ECSP11011081A (fr)
ES (1) ES2415430T3 (fr)
GE (1) GEP20146064B (fr)
HR (1) HRP20130409T2 (fr)
IL (1) IL212732A (fr)
MA (1) MA32834B1 (fr)
ME (1) ME01144B (fr)
MX (1) MX2011005526A (fr)
MY (1) MY152557A (fr)
NI (1) NI201100102A (fr)
NZ (1) NZ592919A (fr)
PE (1) PE20110831A1 (fr)
PL (1) PL2370442T3 (fr)
PT (1) PT2370442E (fr)
RS (2) RS52810B9 (fr)
SI (1) SI2370442T1 (fr)
SV (1) SV2011003923A (fr)
TN (1) TN2011000254A1 (fr)
UA (1) UA99978C2 (fr)
WO (1) WO2010061329A1 (fr)
ZA (1) ZA201104069B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370442B9 (fr) * 2008-11-26 2013-09-04 Pfizer Inc. 3-Aminocyclopentanecarboxamides en tant que modulateurs des récepteurs de chimiokines
KR101303963B1 (ko) * 2011-04-08 2013-09-05 재단법인 경기과학기술진흥원 (1ｒ,2ｒ,3ｒ)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP2016029038A (ja) * 2014-07-17 2016-03-03 参天製薬株式会社 加齢黄斑変性の予防または治療剤
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲（江蘇）醫藥有限公司 環戊烷化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (fr) 1993-12-06 1995-06-15 Cytel Corporation Peptidomimetiques cs-1, compositions et procedes pour les utiliser
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5462208A (en) 1994-08-01 1995-10-31 The Procter & Gamble Company Two-phase dispensing systems utilizing bellows pumps
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
US5704960A (en) 1995-12-20 1998-01-06 Corning, Inc. Method of forming an optical fiber for reduced polarization effects in amplifiers
GB9603741D0 (en) 1996-02-22 1996-04-24 Lin Mei Treatment of water by electrolysis
CA2259927A1 (fr) 1996-07-12 1998-01-22 Leukosite, Inc. Antagonistes des recepteurs de la chemokine et procedes d'utilisation de ces derniers
WO1998042656A1 (fr) 1997-03-21 1998-10-01 Cytel Corporation Nouveaux composes
WO1998053814A1 (fr) 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
AU728435B2 (en) 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
CA2291762A1 (fr) 1997-05-29 1998-12-03 Merck & Co., Inc. Acide biarylalcanoique utilise en tant qu'inhibiteur de l'adhesion cellulaire
EP0984981B1 (fr) 1997-05-30 2003-12-17 Celltech Therapeutics Limited Derives anti-inflammatoires de tyrosine
AU8163398A (en) 1997-06-23 1999-01-04 Pharmacia & Upjohn Company Inhibitors of alpha4beta1mediated cell adhesion
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
DE60321333D1 (de) * 2002-04-29 2008-07-10 Merck Sharp & Dohme Tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridin-modulatoren der chemokin-rezeptor-aktivität
NZ547316A (en) 2003-12-18 2011-01-28 Incyte Corp 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2564561A1 (fr) 2004-04-28 2005-11-10 Merck & Co., Inc. Modulateurs de l'activite de recepteurs de chimiokines en tetrahydropyranylcyclopentylamide disubstitue en position 3,3
MXPA06014672A (es) 2004-06-28 2007-03-26 Incyte Corp 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas.
UA83142C2 (en) * 2004-06-28 2008-06-10 Инсайт Корпорейшн 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors
KR100856155B1 (ko) * 2004-06-28 2008-09-03 인사이트 코포레이션 케모카인 수용체의 조절자로서의3-아미노사이클로펜탄카복스아마이드
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
EP2370442B9 (fr) * 2008-11-26 2013-09-04 Pfizer Inc. 3-Aminocyclopentanecarboxamides en tant que modulateurs des récepteurs de chimiokines

Also Published As

Publication number Publication date
PT2370442E (pt) 2013-06-27
NZ592919A (en) 2013-05-31
CY1114020T1 (el) 2016-07-27
DK2370442T5 (da) 2013-09-23
KR20110075036A (ko) 2011-07-05
US8293903B2 (en) 2012-10-23
PE20110831A1 (es) 2011-11-20
RS52810B (en) 2013-10-31
EP2370442B9 (fr) 2013-09-04
HRP20130409T2 (hr) 2013-11-22
BRPI0920936A2 (pt) 2020-08-11
US20110144129A1 (en) 2011-06-16
ME01144B (me) 2013-03-20
MY152557A (en) 2014-10-31
HRP20130409T1 (en) 2013-06-30
IL212732A0 (en) 2011-07-31
JP5108153B2 (ja) 2012-12-26
EP2370442B1 (fr) 2013-04-24
MX2011005526A (es) 2011-06-06
SI2370442T1 (sl) 2013-06-28
CL2011001223A1 (es) 2011-09-02
WO2010061329A1 (fr) 2010-06-03
IL212732A (en) 2016-06-30
RS52810B8 (sr) 2019-08-30
PL2370442T3 (pl) 2013-08-30
SV2011003923A (es) 2011-07-28
EA020470B1 (ru) 2014-11-28
ES2415430T3 (es) 2013-07-25
AP3113A (en) 2015-01-31
AU2009321221A1 (en) 2010-06-03
CU20110121A7 (es) 2013-05-31
CA2743030A1 (fr) 2010-06-03
AU2009321221B2 (en) 2013-04-04
EP2370442A1 (fr) 2011-10-05
GEP20146064B (en) 2014-03-25
ZA201104069B (en) 2012-02-29
US20130197008A1 (en) 2013-08-01
ES2415430T9 (es) 2013-11-25
UA99978C2 (en) 2012-10-25
CU24022B1 (es) 2014-07-30
CR20110275A (es) 2011-07-01
CA2743030C (fr) 2013-10-22
JP2012509931A (ja) 2012-04-26
NI201100102A (es) 2011-09-27
AP2011005732A0 (en) 2011-06-30
CO6361921A2 (es) 2012-01-20
KR101374412B1 (ko) 2014-03-17
DOP2011000154A (es) 2011-07-31
ECSP11011081A (es) 2011-12-30
DK2370442T3 (da) 2013-06-17
CN102227429B (zh) 2014-05-28
US8946413B2 (en) 2015-02-03
EA201170721A1 (ru) 2011-12-30
CN102227429A (zh) 2011-10-26
MA32834B1 (fr) 2011-11-01
HK1161261A1 (en) 2012-08-24
RS52810B9 (sr) 2019-06-28

Similar Documents

Publication Publication Date Title
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
TN2011000254A1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
MA35245B1 (fr) Pyridin-2-amides utiles comme agonistes de cb2
SMP201100019B (it) Composti organici
EA201000113A1 (ru) Пиразольные соединения
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
EA201070786A1 (ru) Бензофуропиримидиноны
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
MA32903B1 (fr) Inhibiteurs de proteine-kinases
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
JO3116B1 (ar) مشتق بيرازولوكينولين كمثبطات ل pde9
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
CY1111671T1 (el) Ετεροκυκλικη ενωση
ATE459622T1 (de) Tropanverbindungen
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201190293A1 (ru) Пролекарства триптолида
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
IN2012DN00765A (fr)
UY30788A1 (es) Compuestos quimicos